Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139‐Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection
Michel Bazinet, Victor Pântea, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Mark Anderson, Jeff Gersch, Vera Holzmayer, Carina Elsner, Adalbert Krawczyk, Mary C. Kuhns, Gavin Cloherty, Ulf Dittmer, Andrew Vaillant – 13 November 2020 – The nucleic acid polymer REP 2139 inhibits assembly/secretion of hepatitis B virus (HBV) subviral particles. Previously, REP 2139‐Ca and pegylated interferon (pegIFN) in HBV/hepatitis delta virus (HDV) coinfection achieved high rates of HDV RNA and hepatitis B surface antigen (HBsAg) loss/seroconversion in the REP 301 study (NCT02233075).